trending Market Intelligence /marketintelligence/en/news-insights/trending/agu3zi3ymfmhlgysbclr0q2 content esgSubNav
In This List

Cronos Group, Ginkgo Bioworks tie up on cannabinoid production

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Cronos Group, Ginkgo Bioworks tie up on cannabinoid production

Cronos Group Inc. and Ginkgo Bioworks Inc. are collaborating to produce cultured cannabinoids.

Under the exclusive partnership, Ginkgo, a Boston-based biotechnology company, will work with Cronos on the research and development of microorganisms capable of producing certain target cannabinoids.

Cronos will fund certain R&D and foundry expenses expected to be about US$22 million, subject to the achievement of certain milestones.

Upon Ginkgo's demonstration that the microorganisms are capable of producing the target cannabinoids above a minimum productivity level, Cronos will issue up to about 14.7 million common shares.

Assuming all milestones are met, the transaction's value would total US$100 million.

Cronos will have the exclusive right to use and commercialize the key patented intellectual property related producing the target cannabinoids globally.

Cronos, a Toronto-based cannabis company, intends to produce and distribute the target cannabinoids globally and has received confirmation that this method of production is permitted under the Cannabis Act of Canada.